June 22, 2021—Epredia and Aiforia announced they have entered into a commercial distribution agreement for Aiforia’s portfolio of preclinical and clinical pathology tools. Aiforia aims to equip pathologists with AI-powered, secure, and scalable cloud-based software for high-precision image analysis. Its solutions aim to enhance the speed and accuracy of pharmaceutical drug development and cancer diagnostics.
The terms of the agreement include segment exclusivity for distribution in Japan, Germany, U.K., Italy, Spain, Sweden, Norway, Denmark, Iceland, France, and the United States. The products will be available as part of Epredia’s digital pathology portfolio, which includes the CE-marked 3DHistech P1000 WSI scanner.
“With their global presence in the pathology market and our expertise in delivering AI-based solutions for pathologists, Epredia is the ideal commercial partner to help us broaden the international reach of Aiforia’s powerful AI software to pathologists working in clinical diagnostics and preclinical drug development,” Jukka Tapaninen, CEO of Aiforia, said in a press statement. “Our mission is to become a global leader in AI-assisted image analysis to improve the efficiencies of healthcare systems and enable better patient outcomes.”
According to Aiforia, more than 3,000 pathologists and scientists in more than 50 countries use its software.